Conduct Hit-to-Lead Progression Studies on Interventional Agents: Identification of Anti-HIV Lead Compounds

对介入药物进行从先导化合物到先导化合物的进展研究：抗 HIV 先导化合物的鉴定

• 批准号: 10267147
• 负责人: SUSAN SCHADER
• 金额: $ 75万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-21 至 2021-09-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10267147
• 关键词: Academia; Antiviral Agents; Biological Assay; Cell Line; Characteristics; Contracts; Development; Dose; Excretory function; Exhibits; HIV; Human; Intervention; Lead; Local Microbicides; Location; Metabolism; National Institute of Allergy and Infectious Disease; Performance; Peripheral Blood Mononuclear Cell; Primates; Private Sector; Public Health; Resources; SIV; Source; Structure; Structure-Activity Relationship; T-Lymphocyte; Testing; Therapeutic; Virus; Virus Replication; absorption; analog; compound 30; cytotoxicity; high throughput screening; in vitro testing; macrophage; novel therapeutics; preclinical development; public health priorities; response; therapeutic candidate

n Vitro Testing Resource for HIV Therapeutics and Topical Microbicides: The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides in vitro testing, in standard and HTS formats, and conducts preclinical development studies to identify promising anti‐HIV therapeutics and topical microbicides.

N艾滋病毒治疗药物和局部杀微生物剂的体外检测资源：开发和引入针对艾滋病毒的新疗法和局部杀微生物剂仍然是公共卫生的高度优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界、私营部门或其他来源的有前途的治疗性和局部杀微生物剂候选药物的临床前开发。该合同提供标准和HTS格式的体外测试，并进行临床前开发研究，以确定有前景的抗艾滋病毒治疗药物和局部杀微生物剂。